Philip Morris International Inc (PM) — closed signal from April 21, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 20, 2026 — +23.7% at the close.
Predicted vs. what happened
What happened
Reached its target in 20 days.
The thesis — published April 21, 2026
Philip Morris is a defensive consumer company that may be set up to bounce in the next few months. Interest is focused on IQOS after the FDA renewed its lower-risk claim and favorable brokerage comments. The stock has cooled, so a modest rebound is plausible if earnings back the smoke-free transition story.
Primary drivers
- IQOS progress drives the company's move toward smoke-free products
- FDA renewal strengthens the company's product messaging and positioning
- Positive brokerage notes keep attention on the upcoming earnings window
- A recent price reset has reduced short-term downside risk
How it played out
PM: target reached in 20 days
Lyra published PM at $155.80 with expected growth of 12%. The thesis pointed to IQOS progress, the FDA renewal, favorable brokerage notes, and a recent price reset. It expected earnings to support the shift toward smoke-free products.
The stock reached the $173.06 target in 20 days. It later peaked at $194.90 on July 20, a gain of 25.1%, and ended the window at $192.72. The thesis played out and exceeded its stated target.
What happened during the window
On April 22, 2026, Philip Morris reported first-quarter adjusted diluted earnings per share of $1.96, up 16.0%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.